Newland Pharmaceutical Co., Ltd. (301277.SZ)

12.98 +0.10 (+0.78%) At close: 03:04PM CST

Newland Pharmaceutical Co., Ltd.

East side of the southern section of Weiwu Road
Changge City 461500
China
86 37 4610 3777
https://www.newlandpharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 1,010

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Luwei Zhang	GM & Director	N/A	N/A	1971
Mr. Chao Liu	Deputy GM & Director	N/A	N/A	1986
Mr. Jindeng Li	Director & Board Secretary	N/A	N/A	1980

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers intermediates, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, lidocaine, febuxostat, esomeprazole sodium, and esomeprazole magnesium. The company was formerly known as Henan Newland Pharmaceutical Co., Ltd. and changed its name to Newland Pharmaceutical Co., Ltd. in June 2023. Newland Pharmaceutical Co., Ltd. was founded in 2005 and is based in Changge City, China.

Corporate governance

Newland Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.